
Sanofi is exploring a $35B–$43B takeover of Insmed and its blockbuster lung drug Brinsupri as the French pharma giant braces for Dupixent’s looming patent expiration.
Click the title above to open the Pharmaceutical Executive January 2018 issue in an interactive PDF format.
almost 9 years ago
Changing Skies: Pharm Exec’s 2018 Industry Forecastalmost 9 years ago
Q&A: From Gleevec to CAR-Talmost 9 years ago
Prices and Competition to Shape the Year Aheadalmost 9 years ago
CAR-T Concerns for Continued Successalmost 9 years ago
New Year, Next Steps in Digital Transformationalmost 9 years ago
Food for Thought in Cancer Fightalmost 9 years ago
Parting Arrangementsalmost 9 years ago
Country Report: Switzerland




